Literature DB >> 33930293

SARS-CoV-2 RNA: Exclusive friends and common foes.

Emmanuelle V LeBlanc1, Che C Colpitts2.   

Abstract

Infection with SARS-CoV-2 sets off a molecular arms race between virus replication and host cell defense. In this issue of Cell, Flynn, Belk, et al. integrate an advanced large-scale RNA-centered approach with custom CRISPR screens to functionally characterize the interactome of the SARS-CoV-2 RNA genome during infection.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33930293      PMCID: PMC8082805          DOI: 10.1016/j.cell.2021.04.009

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


Main text

Viruses employ a wide range of strategies to replicate within cells. SARS-CoV-2 is a single-stranded, positive-sense RNA virus that coopts the host protein synthesis machinery for translation of its RNA genome. A range of cellular cofactors are engaged for efficient replication and production of progeny virions. At the same time, many host proteins function to detect and restrict virus infection. Extensive efforts have been undertaken to characterize SARS-CoV-2 proteins and their interactions with host factors, yet a gap remained in the understanding of how cellular factors interact with the viral genome. Recent studies have endeavored to elucidate the interactions between SARS-CoV-2 viral RNA (vRNA) and host cell proteins (Flynn et al., 2021; Labeau et al., 2021; Lee et al., 2020; Schmidt et al., 2021). In this issue of Cell, Flynn, Belk, et al. explore the vRNA interactome during SARS-CoV-2 infection using comprehensive identification of RNA-binding proteins by mass spectrometry (ChIRP-MS) and functionally analyze the identified RNA-host protein interactions (Figure 1 ) (Flynn et al., 2021).
Figure 1

Insights from SARS-CoV-2 RNA-host protein interactome

Comprehensive identification of RNA-binding proteins by mass spectrometry (ChIRP-MS) in SARS-CoV-2-susceptible cells lines (left) was leveraged to identify host factors that bind the viral RNA genome during active infection. Integration of these findings with ChIRP-MS data for other RNA viruses and functional screens by targeted CRISPR approaches resulted in several key findings (right).

Insights from SARS-CoV-2 RNA-host protein interactome Comprehensive identification of RNA-binding proteins by mass spectrometry (ChIRP-MS) in SARS-CoV-2-susceptible cells lines (left) was leveraged to identify host factors that bind the viral RNA genome during active infection. Integration of these findings with ChIRP-MS data for other RNA viruses and functional screens by targeted CRISPR approaches resulted in several key findings (right). The authors designed over 100 oligonucleotide probes, capturing the full length of the SARS-CoV-2 RNA genome, which they used to enrich for vRNA-interacting host proteins in two cell lines susceptible to SARS-CoV-2 infection. The use of two cell lines and extensive probe coverage enabled identification of 309 high-confidence interactors, expanding on the 104 RNA-binding host proteins identified in a recent RNA antisense purification and quantitative mass spectrometry (RAP-MS) analysis (Schmidt et al., 2021). Although both studies identified host factors in diverse functional categories that associated with the vRNA, there is little overlap between the vRNA-protein interactome and the viral-host protein-protein interactome (Gordon et al., 2020). This demonstrates that SARS-CoV-2 RNA and proteins interact with different sets of host proteins, an important distinction in understanding SARS-CoV-2 biology. Given that neither of these RNA-centered investigations were performed in cells derived from the lung, Flynn et al. (2021) sought to validate the physiological relevance of their findings by analyzing previously published single-cell RNA sequencing profiles from primary human lung cells (Travaglini et al., 2020). In those data, they detected expression of >95% of their human ChIRP-MS hits in SARS-CoV-2 target cells, including lung epithelial club and ciliated cells and alveolar cells. Thus, the majority of the identified host factors may be relevant during SARS-CoV-2 infection of lung cells, warranting future investigations in human lung cell lines or more physiologically relevant models. Furthermore, defects in innate immunity in the two cell lines used, Vero E6 (due to lack of type I interferon production) and Huh7.5 (due to mutational inactivation of RIG-I), argues for confirmation studies in innate immune-competent models for a comprehensive understanding of the interplay between cellular antiviral immune responses and the SARS-CoV-2 genome. To better understand whether the identified RNA-protein interactions were conserved or virus specific, Flynn, Belk, et al. placed their SARS-CoV-2 ChIRP-MS dataset into context with previously published ChIRP-MS data (Ooi et al., 2019) on three other positive-sense RNA viruses (dengue virus, Zika virus, and rhinovirus). They found that ribonucleoproteins robustly interacted with all four viruses, whereas SARS-CoV-2 was enriched for mitochondrial and proteasomal proteins. Many factors related to intracellular vesicles and trafficking strongly associated with SARS-CoV-2 vRNA, and some were conserved across all RNA viruses that were evaluated. This is consistent with intracellular membrane remodeling by positive-sense RNA viruses to generate replication organelles for protected vRNA replication and transcription. The authors next sought to functionally characterize the vRNA-interacting host proteins by analyzing previous genome-wide CRISPR perturbation data (Wei et al., 2021). They bolstered those findings with a custom screen, targeting nearly all of the proteins in the SARS-CoV-2 RNA interactome, to define factors that functionally impact virus replication. This approach revealed that most of the identified RNA-binding proteins exert antiviral effects, suggesting that a notable proportion of the interactions between vRNA and host proteins function to restrict viral infection, as opposed to virally derived RNA hijacking host cell proteins for productive viral replication. Nonetheless, a smaller set of eight validated pro-viral proteins was identified, with SMARCA4, a transcription activator, as the top hit. Corroboration of these data with pharmacological inhibition of identified pro-viral proteins would validate their roles in viral infection and provide potential new directions for antiviral therapies. Along these lines, Schmidt et al. (2021) demonstrated that pharmacological inhibition of several vRNA-binding proteins identified in their RAP-MS study inhibited SARS-CoV-2 replication in two susceptible cell lines, including a lung epithelial cell line. The aggregated ChIRP-MS data showed that most of the validated antiviral proteins interact with other RNA viruses, suggesting a shared initial host response to vRNA that extends beyond well-known pattern recognition receptors. The authors conducted functional targeted CRISPR screens with six additional RNA viruses, including enveloped and non-enveloped viruses with positive- and negative-sense genomes, to compare functional conservation of SARS-CoV-2 pro- and antiviral factors. Interestingly, many proteins have shared antiviral roles against multiple viruses, and some are conserved across all seven viruses, including coronaviruses and influenza A virus. In contrast, vRNA-interacting proteins with pro-viral roles were more often virus-specific, with many involved in viral entry. Finally, the RNA-centered and CRISPR-based screening approaches established a functional connection between SARS-CoV-2 RNA and the mitochondria, particularly mitochondrial matrix proteins. Electron microscopy of Huh7.5 cells during SARS-CoV-2 infection revealed morphological changes to the mitochondria. The functional role of identified mitochondrial proteins was investigated by a targeted CRISPR approach in Vero E6 cells across seven RNA virus infections, and a number of mitochondrial proteins were found to antagonize replication of multiple viruses, consistent with a role for mitochondria as a platform for host innate immune responses against RNA viruses. Future studies in innate immune competent cells are warranted to decipher the interplay between interferon-mediated innate antiviral responses and the observed viral antagonism by mitochondrial factors. Overall, Flynn, Belk, et al. provide a highly comprehensive landscape of host protein interactions with SARS-CoV-2 RNA during infection. Combined with the recent work of Schmidt et al. (2021), these studies highlight the wealth of information provided by RNA-centric investigations, complementing the growing literature on molecular and cellular mechanisms of SARS-CoV-2 pathogenesis. The integration of the SARS-CoV-2 ChIRP-MS data and targeted CRISPR studies in the context of other large datasets broadens our understanding of the initial cellular response to SARS-CoV-2 and diverse RNA viruses. The functional categorization of pro- and antiviral factors paves the way for detailed mechanistic studies to inform our understanding of virus-host interactions and enable the development of new antiviral strategies.
  7 in total

1.  Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions.

Authors:  Ryan A Flynn; Julia A Belk; Yanyan Qi; Yuki Yasumoto; Jin Wei; Mia Madel Alfajaro; Quanming Shi; Maxwell R Mumbach; Aditi Limaye; Peter C DeWeirdt; Cameron O Schmitz; Kevin R Parker; Elizabeth Woo; Howard Y Chang; Tamas L Horvath; Jan E Carette; Carolyn R Bertozzi; Craig B Wilen; Ansuman T Satpathy
Journal:  Cell       Date:  2021-03-11       Impact factor: 66.850

2.  The SARS-CoV-2 RNA interactome.

Authors:  Sungyul Lee; Young-Suk Lee; Yeon Choi; Ahyeon Son; Youngran Park; Kyung-Min Lee; Jeesoo Kim; Jong-Seo Kim; V Narry Kim
Journal:  Mol Cell       Date:  2021-04-27       Impact factor: 17.970

3.  The SARS-CoV-2 RNA-protein interactome in infected human cells.

Authors:  Nora Schmidt; Caleb A Lareau; Hasmik Keshishian; Sabina Ganskih; Cornelius Schneider; Thomas Hennig; Randy Melanson; Simone Werner; Yuanjie Wei; Matthias Zimmer; Jens Ade; Luisa Kirschner; Sebastian Zielinski; Lars Dölken; Eric S Lander; Neva Caliskan; Utz Fischer; Jörg Vogel; Steven A Carr; Jochen Bodem; Mathias Munschauer
Journal:  Nat Microbiol       Date:  2020-12-21       Impact factor: 17.745

4.  An RNA-centric dissection of host complexes controlling flavivirus infection.

Authors:  Yaw Shin Ooi; Karim Majzoub; Ryan A Flynn; Miguel A Mata; Jonathan Diep; Jason Kenichi Li; Nicholas van Buuren; Neil Rumachik; Alex G Johnson; Andreas S Puschnik; Caleb D Marceau; Luwanika Mlera; Jeffrey M Grabowski; Karla Kirkegaard; Marshall E Bloom; Peter Sarnow; Carolyn R Bertozzi; Jan E Carette
Journal:  Nat Microbiol       Date:  2019-08-05       Impact factor: 17.745

5.  A molecular cell atlas of the human lung from single-cell RNA sequencing.

Authors:  Kyle J Travaglini; Ahmad N Nabhan; Lolita Penland; Rahul Sinha; Astrid Gillich; Rene V Sit; Stephen Chang; Stephanie D Conley; Yasuo Mori; Jun Seita; Gerald J Berry; Joseph B Shrager; Ross J Metzger; Christin S Kuo; Norma Neff; Irving L Weissman; Stephen R Quake; Mark A Krasnow
Journal:  Nature       Date:  2020-11-18       Impact factor: 49.962

6.  Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection.

Authors:  Jin Wei; Mia Madel Alfajaro; Peter C DeWeirdt; Ruth E Hanna; William J Lu-Culligan; Wesley L Cai; Madison S Strine; Shang-Min Zhang; Vincent R Graziano; Cameron O Schmitz; Jennifer S Chen; Madeleine C Mankowski; Renata B Filler; Neal G Ravindra; Victor Gasque; Fernando J de Miguel; Ajinkya Patil; Huacui Chen; Kasopefoluwa Y Oguntuyo; Laura Abriola; Yulia V Surovtseva; Robert C Orchard; Benhur Lee; Brett D Lindenbach; Katerina Politi; David van Dijk; Cigall Kadoch; Matthew D Simon; Qin Yan; John G Doench; Craig B Wilen
Journal:  Cell       Date:  2020-10-20       Impact factor: 66.850

7.  A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

Authors:  David E Gordon; Gwendolyn M Jang; Mehdi Bouhaddou; Jiewei Xu; Kirsten Obernier; Kris M White; Matthew J O'Meara; Veronica V Rezelj; Jeffrey Z Guo; Danielle L Swaney; Tia A Tummino; Ruth Hüttenhain; Robyn M Kaake; Alicia L Richards; Beril Tutuncuoglu; Helene Foussard; Jyoti Batra; Kelsey Haas; Maya Modak; Minkyu Kim; Paige Haas; Benjamin J Polacco; Hannes Braberg; Jacqueline M Fabius; Manon Eckhardt; Margaret Soucheray; Melanie J Bennett; Merve Cakir; Michael J McGregor; Qiongyu Li; Bjoern Meyer; Ferdinand Roesch; Thomas Vallet; Alice Mac Kain; Lisa Miorin; Elena Moreno; Zun Zar Chi Naing; Yuan Zhou; Shiming Peng; Ying Shi; Ziyang Zhang; Wenqi Shen; Ilsa T Kirby; James E Melnyk; John S Chorba; Kevin Lou; Shizhong A Dai; Inigo Barrio-Hernandez; Danish Memon; Claudia Hernandez-Armenta; Jiankun Lyu; Christopher J P Mathy; Tina Perica; Kala Bharath Pilla; Sai J Ganesan; Daniel J Saltzberg; Ramachandran Rakesh; Xi Liu; Sara B Rosenthal; Lorenzo Calviello; Srivats Venkataramanan; Jose Liboy-Lugo; Yizhu Lin; Xi-Ping Huang; YongFeng Liu; Stephanie A Wankowicz; Markus Bohn; Maliheh Safari; Fatima S Ugur; Cassandra Koh; Nastaran Sadat Savar; Quang Dinh Tran; Djoshkun Shengjuler; Sabrina J Fletcher; Michael C O'Neal; Yiming Cai; Jason C J Chang; David J Broadhurst; Saker Klippsten; Phillip P Sharp; Nicole A Wenzell; Duygu Kuzuoglu-Ozturk; Hao-Yuan Wang; Raphael Trenker; Janet M Young; Devin A Cavero; Joseph Hiatt; Theodore L Roth; Ujjwal Rathore; Advait Subramanian; Julia Noack; Mathieu Hubert; Robert M Stroud; Alan D Frankel; Oren S Rosenberg; Kliment A Verba; David A Agard; Melanie Ott; Michael Emerman; Natalia Jura; Mark von Zastrow; Eric Verdin; Alan Ashworth; Olivier Schwartz; Christophe d'Enfert; Shaeri Mukherjee; Matt Jacobson; Harmit S Malik; Danica G Fujimori; Trey Ideker; Charles S Craik; Stephen N Floor; James S Fraser; John D Gross; Andrej Sali; Bryan L Roth; Davide Ruggero; Jack Taunton; Tanja Kortemme; Pedro Beltrao; Marco Vignuzzi; Adolfo García-Sastre; Kevan M Shokat; Brian K Shoichet; Nevan J Krogan
Journal:  Nature       Date:  2020-04-30       Impact factor: 69.504

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.